Skip to main content
. Author manuscript; available in PMC: 2011 Mar 15.
Published in final edited form as: Cancer Res. 2010 Mar 9;70(6):2445–2454. doi: 10.1158/0008-5472.CAN-09-2468

Figure 2.

Figure 2

FLLL31 and FLLL32 are potent inhibitors of STAT3 phosphorylation. A. MDA-MB-231 breast cancer cells and B. PANC-1 pancreatic cancer cells were treated with 2.5 and 5 µM concentrations of FLLL31 and FLLL32 for 24 hours. The Integrated densities of the P-STAT3, STAT3 and cleaved caspase-3 expression were quantified and normalized to GAPDH using ImageJ software. The relatively levels of reduction or increasing of P-STAT3, STAT3, and cleaved caspase-3 were normalized to the DMSO control, which was set as 1.00. C. HMEC and HPDE normal human mammary and pancreatic cells tolerate relatively high dosages of FLLL31 and FLLL32 with no evidence of caspase-3 cleavage. D. FLLL32 inhibits STAT3 phosphorylation in interferon-α-stimulated MDA-MB-453 breast cancer cells. The phosphorylation of both STAT1 and STAT2 is unimpaired. Western blot analysis was analyzed as described in Materials and Methods.